Continuous infusion antipseudomonalbetalactams versus standard short infusions in the treatment of acute infective exacerbations in patients with cystic fibrosis - impact on clinical and microbiological outcomes

Dr Anton Peleg0 个研究点目标入组 120 人开始时间: 2012年9月4日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•1) Patients greater than or equal to 18 years of age,
•2) Pseudomonas aeruginosa isolated in sputum within the last 12 months,
•3) has an acute infective exacerbation, defined by international standards 2 or more of the following in the last 2 weeks:
•change sputum volume or colour,
•increased cough,
•increased dyspnoea,
•increased malaise, fatigue or lethargy,
•anorexia or weight loss,
•decrease in pulmonary function by 10% or more, or
•new radiographic changes

•1) patients < 18 yrs of age,
•2) patients that do not meet the criteria for an acute infective exacerbation,
•3) previous enrolment in the study,
•4) concurrent pulmonary embolism, significant haemoptysis, pneumothorax, or respiratory failure,
•5) impaired renal function with an estimated creatinine clearance < 60 mls/min,
•6) patients allergic to beta-lactam antibiotics,
•7) aminoglycoside contra-indicated,
•8) intravenous antibiotics in the last 2 weeks, prior to this admission,
•9) received more than 24 hours of intravenous antibiotics in this admission,
•10) previous lung transplantation,
•11) pregnancy or lactation, or
•12) inability to consent.

发起方

Dr Anton Peleg